Immunologic and clinical effects of targeting PD-1 in lung cancer

Clinical Pharmacology and Therapeutics

Volumn 96, Issue 2, 2014, Pages 214-223

  Harvey, R D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMP 224; ANTINEOPLASTIC AGENT; ANTIPRURITIC AGENT; ATROPINE; AZACITIDINE; BEVACIZUMAB; BMS 936559; BUDESONIDE; CARBOPLATIN; CISPLATIN; CYTOCHROME P450; DEXAMETHASONE; DIPHENOXYLATE; DOCETAXEL; ENTINOSTAT; ERLOTINIB; GEFITINIB; GEMCITABINE; INFLIXIMAB; INTERLEUKIN 21; IPILIMUMAB; MEDI 4736; MPDL 3280A; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEMETREXED; PIDILIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; STEROID; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADVANCED CANCER; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; COLITIS; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG DISPOSITION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENDOCRINE DISEASE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HORMONE SUBSTITUTION; HUMAN; HYPERGLYCEMIA; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNE RESPONSE; LIVER TOXICITY; LOW DRUG DOSE; LUNG CANCER; LUNG DISEASE; LUNG EDEMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAXIMUM TOLERATED DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; ORAL IMMUNOTHERAPY; OVERALL SURVIVAL; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; REVIEW; SKIN DISEASE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; VOMITING;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84904855312     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.74     Document Type: Review

References (66)

1. Molina, J.R., Yang, P., Cassivi, S.D., Schild, S.E. & Adjei, A.A. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584-594 (2008 (Pubitemid 351720831)
2. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines̊). Non-small cell lung cancer. Version 2, 2013. http: //www.nccn.com. Accessed 8 August 2013
3. Jänne, P.A., Engelman, J.A. & Johnson, B.E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J. Clin. Oncol. 23, 3227-3234 (2005 (Pubitemid 46211347)
4. Yervoẙ (ipilimumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, 2013. http: //www.yervoy.com/pdf/pi-yervoy.pdf. Accessed 2 December 2013
5. Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010
6. Jonasch, E. et al. State of the science: An update on renal cell carcinoma. Mol. Cancer Res. 10, 859-880 (2012
7. Al-Moundhri, M., O'Brien, M. & Souberbielle, B.E. Immunotherapy in lung cancer. Br. J. Cancer 78, 282-288 (1998 (Pubitemid 28336410)
8. Murphy, K. Janeway's Immunobiology 8th edn. (Garland Science, New York, 2011
9. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012
10. Keir, M.E., Butte, M.J., Freeman, G.J. & Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008 (Pubitemid 351600389)
11. Jadus, M.R. et al. Lung cancer: A classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin. Dev. Immunol. 2012, 160724 (2012
12. Zou, W. & Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8, 467-477 (2008 (Pubitemid 351733418)
13. Benson, D.M. Jr et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116, 2286-2294 (2010
14. Blank, C. et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int. J. Cancer 119, 317-327 (2006
15. Dong, H. et al. Tumor-Associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002
16. Rozali, E.N., Hato, S.V., Robinson, B.W., Lake, R.A. & Lesterhuis, W.J. Programmed death ligand 2 in cancer-induced immune suppression. Clin. Dev. Immunol. 2012, 656340 (2012
17. Karim, R. et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin. Cancer Res. 15, 6341-6347 (2009
18. Zhang, Y., Huang, S., Gong, D., Qin, Y. & Shen, Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell. Mol. Immunol. 7, 389-395 (2010
19. Wang, W., Lau, R., Yu, D., Zhu, W., Korman, A. & Weber, J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int. Immunol. 21, 1065-1077 (2009
20. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T. & Minato, N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99, 12293-12297 (2002
21. Iwai, Y., Terawaki, S. & Honjo, T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17, 133-144 (2005 (Pubitemid 40246578)
22. Hirano, F. et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65, 1089-1096 (2005 (Pubitemid 40216472)
23. Okudaira, K. et al. Blockade of B7-H1 or B7-DC induces an anti-Tumor effect in a mouse pancreatic cancer model. Int. J. Oncol. 35, 741-749 (2009
24. Selby, M. et al. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J. Clin. Oncol. 31, abstr. 3061 (2013
25. Curran, M.A., Montalvo, W., Yagita, H. & Allison, J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 107, 4275-4280 (2010
26. Woo, S.R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917-927 (2012
27. Jure-Kunkel, M. et al. Nonclinical evaluation of the combination of mouse IL-21 and anti-mouse CTLA-4 or PD-1 blocking antibodies in mouse tumor models. J. Clin. Oncol. 31, abstr. 3019 (2013
28. West, E.E. et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 123, 2604-2615 (2013
29. Strome, S.E. et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63, 6501-6505 (2003 (Pubitemid 37255203)
30. Li, B., VanRoey, M., Wang, C., Chen, T.H., Korman, A. & Jooss, K. Antiprogrammed death-1 synergizes with granulocyte macrophage colonystimulating factor-secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin. Cancer Res. 15, 1623-1634 (2009
31. Mangsbo, S.M., Sandin, L.C., Anger, K., Korman, A.J., Loskog, A. & Tötterman, T.H. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J. Immunother. 33, 225-235 (2010
32. Mkrtichyan, M. et al. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-Tumor vaccine effects through novel mechanisms. Eur. J. Immunol. 41, 2977-2986 (2011
33. Webster, W.S. et al. Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. J. Immunol. 179, 2860-2869 (2007
34. Zhou, Q. et al. Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J. Immunol. 185, 5082-5092 (2010
35. Curiel, T.J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9, 562-567 (2003 (Pubitemid 36597102)
36. Wong, R.M. et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int. Immunol. 19, 1223-1234 (2007 (Pubitemid 47500645)
37. Rosenblatt, J. et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 34, 409-418 (2011
38. Nomi, T. et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin. Cancer Res. 13, 2151-2157 (2007 (Pubitemid 46649885)
39. McDermott, D.F. & Atkins, M.B. PD-1 as a potential target in cancer therapy. Cancer Med. 2, 662-673 (2013
40. Clinicaltrials.gov http: //clinicaltrials.gov /ct2/show/NCT01903993. Accessed 14 February 2014
41. Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14, 3044-3051 (2008
42. Brahmer, J.R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012
43. Garon, E.B. et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). Abstr. MO18.02. https: //www.webges.com/cview/ library/wclc/home. Accessed 2 December 2013
44. Hamid, O. et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013
45. Horn, L. et al. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with nonsmall cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1). Abstr. MO18.01. https: //www.webges.com/cview/library/wclc/ home. Accessed 2 December 2013
46. Infante, J.R. et al. Clinical and pharmacodynamic (PD) results of a phase I trial with AMP-224 (B7-DC Fc) that binds to the PD-1 receptor. J. Clin. Oncol. 31, abstr. 2013 (2013
47. Smothers, J.F., Hoos, A., Langermann, S., Marshall, S., May, R. & Fleming, M.E. AMP-224, a fusion protein that targets PD-1. Ann. Oncol. 24, abstr. L02.04 (2013
48. Stewart, R.A. et al. MEDI4736: Delivering effective blockade of immunosupression to enhance tumour rejection: Monoclonal antibody discovery and preclinical development. Cancer Res. 71, abstr. LB-158 (2011
49. Topalian, S.L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012
50. Brahmer, J.R. et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): Overall survival and long-Term safety in a phase 1 trial. Abstr. MO18.03. https: //www.webges.com/cview/ library/ wclc/home. Accessed 2 December 2013
51. Rizvi, N.A. et al. A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). Abstr. 8072. http: //meetinglibrary.asco.org/content/84225. Accessed 2 December 2013
52. Wolchok, J.D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133 (2013
53. Christensen, H. & Hermann, M. Immunological response as a source to variability in drug metabolism and transport. Front. Pharmacol. 3, 8 (2012
54. Yervoy (ipilizumab) Summary of Product Characteristics http: //www. medicines.org.uk/emc/medicine/24779. Accessed 5 September 2013
55. Evers, R. et al. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: A white paper. Drug Metab. Dispos. 41, 1598-1609 (2013
56. Lee, J.I., Zhang, L., Men, A.Y., Kenna, L.A. & Huang, S.M. CYP-mediated therapeutic protein-drug interactions: Clinical findings, proposed mechanisms and regulatory implications. Clin. Pharmacokinet. 49, 295-310 (2010
57. Cepeda, V., Fuertes, M.A., Castilla, J., Alonso, C., Quevedo, C. & Pérez, J.M. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer. Agents Med. Chem. 7, 3-18 (2007 (Pubitemid 46062402)
58. Bang, Y.J. The potential for crizotinib in non-small cell lung cancer: A perspective review. Ther. Adv. Med. Oncol. 3, 279-291 (2011
59. Shepherd, F.A. et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005 (Pubitemid 41058344)
60. Eisenhauer, E.A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009
61. Zitvogel, L., Tesniere, A. & Kroemer, G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715-727 (2006 (Pubitemid 44453458)
62. Saenger, Y.M. & Wolchok, J.D. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: Patient cases. Cancer Immun. 8, 1 (2008
63. Wolchok, J.D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009
64. Weber, J. Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events. Oncologist 12, 864-872 (2007 (Pubitemid 47328229)
65. Weber, J.S., Kähler, K.C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691-2697 (2012
66. Herbst, R.S. et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J. Clin. Oncol. 31, abstr. 3000 (2013.